NASH field: Novo Nordisk Somautide and Gilead strong combination

Original title: NASH Field: Novo Nordisk Somalutide and Gilead Strong JointI, Gilead, Noor and Nord Strong JointApril 12, 2019, Novo nor Nordisk on semalutide (long-lasting GLP-1 analogu) ) A cooperation agreement with Gilead's cilofexor (FXR agonist) (Faniol X receptor agonist) (Phase 2 clinical), firsocostat (ACC inhibitor) (Phase 2 clinical) co-treatment NASH (nonsalcoholicteatoitis)Gilead has made a heavy contribution to liver disease such as NASH, and a number of new drugs are currently under development, while working closely with other biopharmaceutical companiesOn April 16th, an early development partnership was reached with InsitroII, domestic enterprises in development:Novartis LMB763,Zhengda Tianqing (TQA3526),Microcore (ASK1-CS17919),Guangshengtang (GST-HG-HG151, etc.),Dongsun, Zeyi,Shanghai Tuo-Yi Bio, Life Pharmaceuticals,Jun-Tai (HTD1801), first, For Da, Qingdao Huanghai Pharmaceuticals,New Elemental Pharmaceuticals, Tianshili (FGF21), Colum Pharmaceuticals (PPAR),Paige Bio (GLP-1), Golibio (with 3-VBiosciences) FASN inhibitors),Kangzhe Pharmaceuticals (introduced Can-Fit e Company CF-102, A3 adenosine receptor (A3AR) agonist), Hepu Bio(Several NASH are developed by WuXi) three, the forefront of international NASH research: 1 Current guidelines recommend thetherapy: UDCA: Bear deoxycholic acid, vitamin E, pyridocidarin, metformin, GLP-1RA, omega 3 fatty acids, statins, Pentoxifylline: ketone cocoa base, OCA obertic acid, etc 2 Partly ahead of NASH's Pipeline: Gilead's ASK1 inhibitor Selonsertib, announced the first Phase III clinical STELLAR-4 failure on February 11, 2019! February 19, 2019, Intercept disclosed a phase 3 trial of obetic acid (OCA), which showed that reaching the main endpoint could significantly improve liver fibrosis expect OCA to emerge from the ring and become a precedent for NASH drugs reference: NMPA/CDE; Pharmaceutical Melt data, Pharnex Datamonitor; Drug Melting Current and futurespharmacologicalrapies for NAFLD/NASH
Jentergastrool.2018;53 (3): 362-376.
doi:10.1007/s00535-017-1415-1
https:// https://globenewswire.com/news-release/2019/02/19/1734111/0/en/Intercept-Announces-Positive-Topline-Results-from-Pivotal-Phase-3-REGENERATE-Study-of-Obeticholic-Acid-in-Patients-with-Liver-Fibrosis-Due-to-NASH.html